Access the full text.
Sign up today, get DeepDyve free for 14 days.
(1998)
Systemic antifungal agents. Drug interactions of clinical significance
K. Olkkola, J. Backman, P. Neuvonen (1995)
Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.Clinical pharmacology and therapeutics, 55 5
T. Bjornsson, J. Callaghan, H. Einolf, V. Fischer, Lawrence Gan, S. Grimm, J. Kao, S. King, G. Miwa, L. Ni, Gondi Kumar, J. McLeod, R. Obach, S. Roberts, A. Roe, Anita Shah, F. Snikeris, J. Sullivan, D. Tweedie, J. Vega, J. Walsh, S. Wrighton (2003)
The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.Drug metabolism and disposition: the biological fate of chemicals, 31 7
K. Lown, D. Bailey, R. Fontana, S. Janardan, C. Adair, Laurie Fortlage, Morton Brown, Wensheng Guo, P. Watkins (1997)
Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression.The Journal of clinical investigation, 99 10
DeVane DeVane, Nemeroff Nemeroff (2001)
Clinical pharmacokinetics of quetiapine: an atypical antipsychoticClin Pharmacokinet, 40
T. Prior, P. Chue, P. Tibbo, G. Baker (1999)
Drug metabolism and atypical antipsychoticsEuropean Neuropsychopharmacology, 9
J. Markowitz, Candace Brown, Thea Moore (1999)
Atypical Antipsychotics Part I: Pharmacology, Pharmacokinetics, and Efficacy, 33
L. Moltke, D. Greenblatt, J. Harmatz, S. Duan, L. Harrel, M. Cotreau-Bibbo, G. Pritchard, C. Wright, R. Shader (1996)
Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole.The Journal of pharmacology and experimental therapeutics, 276 2
(2004)
Seroquel (quetiapine fumarate
S. Potkin, P. Thyrum, G. Alva, R. Bera, C. Yeh, L. Arvanitis (2002)
The Safety and Pharmacokinetics of Quetiapine When Coadministered With Haloperidol, Risperidone, or ThioridazineJournal of Clinical Psychopharmacology, 22
D. Newton, R. Wang, A. Lu (1995)
Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.Drug metabolism and disposition: the biological fate of chemicals, 23 1
Y. Wong, B. Ewing, P. Thyrum, C. Yeh (1997)
564 Multiple-dose pharmacokinetics of ‘seroquel’ (quetiapine) in schizophrenic men and womenSchizophrenia Research, 24
Candace Brown, J. Markowitz, Thea Moore, N. Parker (1999)
Atypical Antipsychotics: Part II Adverse Effects, Drug Interactions, and Costs, 33
C. Mignat (1997)
Clinically Significant Drug Interactions with New Immunosuppressive AgentsDrug Safety, 16
J. Williams, B. Ring, B. Ring, Varon Cantrell, Varon Cantrell, David Jones, J. Eckstein, J. Eckstein, K. Ruterbories, K. Ruterbories, M. Hamman, M. Hamman, S. Hall, S. Hall, S. Wrighton, S. Wrighton (2002)
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.Drug metabolism and disposition: the biological fate of chemicals, 30 8
D. Boulton, C. DeVane, H. Liston, John Markowitz (2002)
In vitro P-glycoprotein affinity for atypical and conventional antipsychotics.Life sciences, 71 2
A. Varhe, K. Olkkola, P. Neuvonen (1994)
Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazoleClinical Pharmacology & Therapeutics, 56
Venkatakrishnan Venkatakrishnan, Von Moltke Von Moltke, Greenblatt Greenblatt (2000)
Effects of the antifungal agents on oxidative drug metabolism: clinical relevanceClin Pharmacokinet, 38
J. Shaw, J. Lewis, S. Pascal, Rakesh Sharma, R. Rodriguez, Ramiro Guillen, Marilyn Pupo-Guillen (2001)
A study of quetiapine: efficacy and tolerability in psychotic adolescents.Journal of child and adolescent psychopharmacology, 11 4
D. Greenblatt, L. Moltke, J. Harmatz, P. Mertzanis, J. Graf, A. Durol, Molly Counihan, B. Roth‐Schechter, R. Shader (1998)
Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazoleClinical Pharmacology & Therapeutics, 64
Y. Wong, B. Ewing, P. Thyrum, C. Yeh (1997)
566 The effect of phenytoin and cimetidine on the pharmacokinetics of seroquelSchizophrenia Research, 24
E. Wang, K. Lew, C. Casciano, R. Clement, W. Johnson (2002)
Interaction of Common Azole Antifungals with P GlycoproteinAntimicrobial Agents and Chemotherapy, 46
R. Bertz, G. Granneman (1997)
Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic InteractionsClinical Pharmacokinetics, 32
B. Mcconville, Lynn Carrero, D. Sweitzer, L. Potter, R. Chaney, K. Foster, M. Sorter, L. Friedman, K. Browne (2003)
Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial.Journal of child and adolescent psychopharmacology, 13 1
K. Venkatakrishnan, L. Moltke, D. Greenblatt (2000)
Effects of the Antifungal Agents on Oxidative Drug MetabolismClinical Pharmacokinetics, 38
J. Goren, G. Levin (1998)
Quetiapine, an Atypical AntipsychoticPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 18
E. Tanaka, S. Hisawa (1999)
Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 systemJournal of Clinical Pharmacy and Therapeutics, 24
S. Grimm, M. Dyroff (1997)
Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase.Drug metabolism and disposition: the biological fate of chemicals, 25 5
(2000)
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Text Revision
Aims To explore the potential for drug interactions on quetiapine pharmacokinetics using in vitro and in vivo assessments. Methods The CYP enzymes responsible for quetiapine metabolite formation were assessed using recombinant expressed CYPs and CYP‐selective inhibitors. P‐glycoprotein (Pgp) transport was tested in MDCK cells expressing the human MDR1 gene. The effects of CYP3A4 inhibition were evaluated clinically in 12 healthy volunteers that received 25 mg quetiapine before and after 4 days of treatment with ketoconazole 200 mg daily. To assess CYP3A4 induction in vivo, 18 patients with psychiatric disorders were titrated to steady‐state quetiapine levels (300 mg twice daily), then titrated to 600 mg daily carbamazepine for 2 weeks. Results CYP3A4 was found to be responsible for formation of quetiapine sulfoxide and N‐ and O‐desalkylquetiapine and not a Pgp substrate. In the clinical studies, ketoconazole increased mean quetiapine plasma Cmax by 3.35‐fold, from 45 to 150 ng ml−1 (mean Cmax ratio 90% CI 2.51, 4.47) and decreased its clearance (Cl/F) by 84%, from 138 to 22 l h−1 (mean ratio 90% CI 0.13, 0.20). Carbamazepine decreased quetiapine plasma Cmax by 80%, from 1042 to 205 ng ml−1 (mean Cmax ratio 90% CI 0.14, 0.28) and increased its clearance 7.5‐fold, from 65 to 483 l h−1 (mean ratio 90% CI 6.04, 9.28). Conclusions Cytochrome P450 3A4 is a primary enzyme responsible for the metabolic clearance of quetiapine. Quetiapine pharmacokinetics were affected by concomitant administration of ketoconazole and carbamazepine, and therefore other drugs and ingested natural products that strongly modulate the activity or expression of CYP3A4 would be predicted to change exposure to quetiapine.
British Journal of Clinical Pharmacology – Wiley
Published: Jan 1, 2006
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.